Overview

A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants

Status:
Completed

Trial end date:
2017-07-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect of the potent cytochrome P-450 (CYP) 3A4 inhibitor (itraconazole) on the single-dose PK of oral TAK-906 maleate.

Phase:

Phase 1

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Treatments:

Cytochrome P-450 CYP3A Inhibitors
Hydroxyitraconazole
Itraconazole
Maleic acid